AstraZeneca has allocated $3.5billion to expand its US manufacturing and research footprint by the end of 2026. The funding ...

The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...

In the US, AstraZeneca has approximately 17,800 employees working across 17 R&D, manufacturing and commercial sites spanning ...

AstraZeneca chief Pascal Soriot has said a deepening criminal probe into his company’s Chinese business is being taken “very ...

Cambridge: AstraZeneca has announced $3.5 billion of capital investment in the United States focused on expanding the Company's research and manufacturing footprint by the end of 2026.

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

AstraZeneca plans a new investment of $2 billion in the U.S., one of the first major foreign companies to shift spending to ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

CAMBRIDGE, Britain — CAMBRIDGE, Britain — Astrazeneca PLC (AZN) on Tuesday reported third-quarter earnings of $1.43 billion. On a per-share basis, the Cambridge, Britain-based company said it had ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...